Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Advanced and Relapsed Germ Cell Tumors
NCT03081923Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab and tremelimumab in germ cell tumor (GCT), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Feb 2017; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT03081923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081923.